Document Detail


Multiple myeloma presenting with acquired factor VIII inhibitor.
MedLine Citation:
PMID:  19551464     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An initial presentation of hematological malignancies associated with autoantibodies is not common, and there is only one documented case of multiple myeloma presenting with acquired FVIII inhibitor for multiple myeloma. In this paper, we describe a second case of multiple myeloma who presented with acquired FVIII inhibitor. A 43-year-old woman was referred to our hematology unit for anemia and an elevated erythrocyte sedimentation rate. Two months before her admission, she had undergone an operation at a local hospital because of ovarian cyst rupture complicated by severe postoperative bleeding. Because coagulation tests had revealed a prolonged partial thromboplastin time which could not be corrected by a mixing test and a decreased FVIII level, a diagnosis of acquired FVIII inhibitor had been made. The patient was hospitalized in our unit for further evaluation. The erythrocyte sedimentation rate was 110 mm/h, serum albumin level 2.5 g/dL, globulin level 5.6 g/dL, and C-reactive protein 47.8 mg/L (0-6). Serum IgG was high, and serum protein electrophoresis showed a monoclonal spike in the gamma region. An IgG-kappa paraprotein was identified by immunofixation of the urine and serum. X-ray films of the bones revealed lytic areas in the skull, pelvis, and lumbar vertebrae. Bone marrow aspiration showed normal cellularity with 40% plasma cell infiltration. The patient was diagnosed with the IgG kappa type of multiple myeloma associated with acquired FVIII inhibitor. In patients presenting with severe bleeding, autoantibodies against FVIII should be considered for the differential diagnosis of bleeding. Clinicians should be alert to the presence of rare underlying neoplastic diseases such as multiple myeloma, in patients with acquired FVIII inhibitor.
Authors:
Ismail Sari; Mehmet Ali Erkurt; Ahmet Ifran; Kursat Kaptan; Cengiz Beyan
Related Documents :
2694424 - Plasma von willebrand factor proteolysis in patients with chronic myeloproliferative di...
1904284 - Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality.
3109524 - Immunologic aberrations, hiv seropositivity and seroconversion rates in patients with h...
1165294 - A five-year study of a haemophilia reference centre.
7072494 - Amyloidosis associated with juvenile rheumatoid arthritis.
8298474 - Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated ma...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2009-06-24
Journal Detail:
Title:  International journal of hematology     Volume:  90     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-24     Completed Date:  2009-11-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  166-9     Citation Subset:  IM    
Affiliation:
Department of Hematology, Pamukkale University Faculty of Medicine, Denizli, Turkey. hisari@pau.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Autoantibodies / blood*,  immunology
Blood Coagulation Factor Inhibitors / immunology*
Factor VIII / immunology*
Female
Hemorrhage / diagnosis,  immunology*
Humans
Immunoglobulin G / blood,  immunology
Immunoglobulin kappa-Chains / blood,  immunology
Multiple Myeloma / blood*,  diagnosis,  immunology*
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Blood Coagulation Factor Inhibitors; 0/Immunoglobulin G; 0/Immunoglobulin kappa-Chains; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Olfactory identification in non-demented elderly population and in mild cognitive impairment: a comp...
Next Document:  Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in local...